Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Authors
Walz, CErben, P
Ritter, M
Bloor, Adrian
Metzgeroth, G
Telford, Nicholas
Haferlach, C
Haferlach, T
Gesk, S
Score, J
Hofmann, W-K
Hochhaus, A
Cross, N C P
Reiter, A
Affiliation
Pathologisches Institut, Ludwig-Maximilians-Universität, München, Germany.Issue Date
2011-08-25
Metadata
Show full item recordAbstract
Imatinib-resistant tyrosine kinase (TK) fusions involving FGFR1, JAK2, or FLT3 are rare but recurrent in patients with eosinophilia-associated neoplasms. We report here 2 male patients with ETV6-FLT3(+) myeloid/lymphoid neoplasms with eosinophilia who were treated with the multitargeted TK inhibitors sunitinib and sorafenib. Patient 1 achieved rapid complete hematologic response and complete cytogenetic response after 3 months of taking sunitinib. A secondary blast phase caused by clonal evolution was diagnosed after 6 months. He achieved a second complete hematologic response after taking sorafenib but relapsed 2 months later. An N841K point mutation within the TK domain of FLT3, previously reported in acute myeloid leukemia and potentially conferring resistance to sorafenib, was subsequently identified. Patient 2 was heavily pretreated according to the initial diagnosis of T-lymphoblastic lymphoma and died in sunitinib-induced pancytopenia. This report highlights the importance of a careful diagnostic workup for eosinophilia-associated neoplasms to evaluate the possibility of TK inhibitor therapy.Citation
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. 2011, 118 (8):2239-42 BloodJournal
BloodDOI
10.1182/blood-2011-03-343426PubMed ID
21705501Type
ArticleLanguage
enISSN
1528-0020ae974a485f413a2113503eed53cd6c53
10.1182/blood-2011-03-343426
Scopus Count
Related articles
- Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
- Authors: Shao H, Wang W, Song J, Tang G, Zhang X, Tang Z, Srivastava J, Shah B, Medeiros LJ, Zhang L
- Issue date: 2020 Dec
- Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
- Authors: Kancha RK, Grundler R, Peschel C, Duyster J
- Issue date: 2007 Oct
- Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
- Authors: Baker SD, Zimmerman EI, Wang YD, Orwick S, Zatechka DS, Buaboonnam J, Neale GA, Olsen SR, Enemark EJ, Shurtleff S, Rubnitz JE, Mullighan CG, Inaba H
- Issue date: 2013 Oct 15
- T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
- Authors: Schoelinck J, Gervasoni J, Guillermin Y, Beillard E, Pissaloux D, Chassagne-Clement C
- Issue date: 2024 May
- Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
- Authors: von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J
- Issue date: 2010 Aug